Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome
Open Access
- 1 June 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 23 (6), 1117-1124
- https://doi.org/10.1681/asn.2011080775
Abstract
Idiopathic nephrotic syndrome resistant to standard treatments remains a therapeutic dilemma in pediatric nephrology. To test whether the anti-CD20 monoclonal antibody rituximab may benefit these patients, we conducted an open-label, randomized, controlled trial in 31 children with idiopathic nephrotic syndrome unresponsive to the combination of calcineurin inhibitors and prednisone. All children continued prednisone and calcineurin inhibitors at the doses prescribed before enrollment, and one treatment group received two doses of rituximab (375 mg/m2 intravenously) as add-on therapy. The mean age was 8 years (range, 2–16 years). Rituximab did not reduce proteinuria at 3 months (change, −12% [95% confidence interval, −73% to 110%]; P=0.77 in analysis of covariance model adjusted for baseline proteinuria). Additional adjustment for previous remission and interaction terms (treatment by baseline proteinuria and treatment by previous remission) did not change the results. In conclusion, these data do not support the addition of rituximab to prednisone and calcineurin inhibitors in children with resistant idiopathic nephrotic syndrome.Keywords
This publication has 44 references indexed in Scilit:
- The Duke Activity Status Index in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2012
- Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndromeClinical and Experimental Immunology, 2011
- TRPC6 Mutations in Children with Steroid-Resistant Nephrotic Syndrome and Atypical PhenotypeClinical Journal of the American Society of Nephrology, 2011
- Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2011
- Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2010
- Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndromeClinical and Experimental Immunology, 2010
- Asymptomatic Reactivation of JC Virus in Patients Treated with NatalizumabThe New England Journal of Medicine, 2009
- Fatal pulmonary fibrosis after rituximab administrationPediatric Nephrology, 2009
- Rituximab Treatment of Adult Patients with Steroid-Resistant Focal Segmental GlomerulosclerosisClinical Journal of the American Society of Nephrology, 2009
- Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 casesPediatric Nephrology, 2008